Published in final edited form as:

Transplantation. 2016 November ; 100(11): 2288–2300. doi:10.1097/TP.0000000000001379.

Impact of immune-modulatory drugs on Treg

Akiko Furukawa, MD[#], Steven A. Wisel, MD[#], and Qizhi Tang, PhD

Department of Surgery, University of California, San Francisco, San Francisco, CA, United States

[#] These authors contributed equally to this work.

Abstract

Immunosuppression strategies that selectively inhibit effector T cells while preserving and even enhancing CD4⁺FOXP3⁺ regulatory T cells (Treg) permit immune self-regulation and may allow minimization of immunosuppression and associated toxicities. Many immunosuppressive drugs were developed before the identity and function of Treg were appreciated. A good understanding of the interactions between Treg and immunosuppressive agents will be valuable to the effective design of more tolerable immunosuppression regimens. This review will discuss preclinical and clinical evidence regarding the influence of current and emerging immunosuppressive drugs on Treg homeostasis, stability, and function as a guideline for the selection and development of Treg-friendly immunosuppressive regimens.

Introduction

The identification of immunosuppressive medications, particularly calcineurin inhibitors (CNI), has allowed the field of transplantation to develop. Contemporaneously, we have learned that the immune system can be re-educated to accommodate changing self and foreign tissues through disarming effector T cells and generation of regulatory T cells (Treg). There are many types of Treg including CD4⁺ and CD8⁺ cells expressing the transcription factor FOXP3 and the IL-10-producing Tr1 cells. In this review, we focus on the CD4⁺FOXP3⁺ subset. These Treg constitutively express CD25, the α chain of the IL-2 receptor that confers high sensitivity to IL-2. Treg are essential for immune homeostasis and tolerance to self and foreign antigens including allografts^{1,2}. Because of substantial toxicity of immunosuppression medications, there has been increasing interest in promoting transplant immune tolerance so that immunosuppression can be minimized or withdrawn. Many immunosuppressants were designed to broadly mitigate T cell function, including that of Treg. This review focuses on the impact of immunosuppressive drugs on Treg with the goal of identifying Treg-supportive immunosuppressive regimens and providing guidelines for rationalized design of therapeutics for promoting immune self-regulation in transplantation.

Corresponding author: Qizhi Tang, PhD, University of California, San Francisco, 513 Parnassus Avenue, HSE520, Box 0780, San Francisco, California 94143, qizhi.tang@ucsf.edu.

Authorship:

They conducted the review of literature and compilation of findings; QT supervised literature review and manuscript preparation, and reviewed all conclusions. AF and SW prepared the manuscript, with review and editing by QT.

Disclosures: The authors declare no conflicts of interest.

Development, homeostasis, and function of Treg

Treg can develop from maturing CD4⁺CD8⁻ thymocytes and from mature CD4⁺ T cells after they exit the thymus. While Treg development in the thymus (tTreg) and in the periphery (pTreg) both depend on signaling through T cell receptors (TCR), there are differences in the role of TCR signaling intensity on these subsets of Treg. In the thymus, strong TCR signaling with CD28 costimulation, just below the threshold for negative selection, promote tTreg lineage commitment³. In the periphery, persistent weak TCR stimulation along with IL-2, transforming growth factor- β (TGF- β) or retinoic acid is conducive to pTreg development⁴, a process abrogated by strong costimulation. pTreg express FOXP3 and cell surface markers similar to that of tTreg. While tTreg also express transcription factor HELIOS and cell surface protein neuropilin 1, pTreg generally do not, although some exceptions have been reported⁵⁻⁹. In addition, DNA in tTreg is demethylated in the Treg-specific demethylated region (TSDR) in the FOXP3 enhancer, whereas TSDR of pTreg is only partially demethylated⁷. The incompletely demethylated TSDR leaves pTreg more prone to lose FOXP3 expression and function. Overall, tTreg are a stable lineage of cells with specificity toward thymically expressed self-antigens; whereas pTreg are a more dynamic population recruited to ensure tolerance to new antigens encountered in the periphery. Both populations are essential to immune tolerance¹⁰.

Treg require IL-2 to maintain their lineage stability, and because Treg do not make IL-2, they are dependent on IL-2 from other T cells and dendritic cells. Treg are highly sensitive to IL-2, due to their constitutively high expression of CD25 and amplified intracellular signal transduction downstream of the IL-2 receptor¹¹. Treg can thus be considered the “first responders” to IL-2, competing with conventional T cells (Tconvs) for IL-2 as a mechanism to prevent unwanted immune responses. Defects in the IL-2 receptor, IL-2 signaling, or limited IL-2 availability leads to Treg destabilization. On the other hand, very high levels of IL-2, either provided therapeutically or because of potent immune activation, override Treg suppression and allow immune responses to proceed. Thus, IL-2 signaling is essential to tolerance mediated by Treg and the level of IL-2 is a critical determinant of immune activation versus tolerance.

Treg can modulate the stimulatory capacity of antigen presenting cells (APCs) by removing CD80 and CD86 from their surface through CTLA-4-mediated transcytosis¹². The resulting reduction of cosimulation increases the threshold for Tconv activation. During an active immune response, TCR and cytokine stimulations induce Treg trafficking to inflammatory sites where they use a broader array of suppressive mechanisms to dampen inflammation and limit collateral tissue damage¹³. Activated Treg can also induce new pTreg with distinct alloantigen specificity leading to an “infectious” spread of tolerance¹⁴.

Immunosuppressive medications inhibit many of these critical Treg pathways described above. This off-target inhibition of Treg may impede tolerance while preventing effector T cells from attacking allografts. However, research in Treg signaling in recent years has revealed some distinct intracellular signaling pathways in Treg versus Tconvs. Knowing these distinctions will guide the use of immunosuppressive drugs to promote Treg.

Immunosuppression for transplantation

Solid organ transplant recipients typically receive a combination immunosuppressive regimen given at the time of transplantation (induction therapy) and during the maintenance phase¹⁵. Induction agents may be broadly classified as depleting or nondepleting depending on whether they act by killing or inhibiting immune cells. Depleting induction agents include anti-thymocyte globulin (Thymoglobulin, Genzyme; Atgam, Pfizer), monoclonal antibodies (mAb) against CD3 (Muromonab, Janssen-Cilag), and anti-CD52 mAb (alemtuzumab; Campath, Genzyme). Non-depleting agents include methylprednisolone and anti-CD25 mAb basiliximab (Simulect, Novartis) and daclizumab (Zenapax, Hoffmann-La Roche). The use of induction immunosuppression strongly suppresses immune response soon after transplant when inflammation associated with surgery and ischemia make the graft most vulnerable to immune attacks¹⁵.

Maintenance therapies vary by type of organ, institutional preference, and organ recipient demographics. A multimodal approach is commonly employed to prevent rejection by blocking immune responses through several pathways. Commonly used immunosuppressive drugs include CNIs, mammalian Target of Rapamycin (mTOR) inhibitors, corticosteroids¹⁶, mycophenolate preparations, CTLA4-Ig, and anti-CD20 mAb. A host of newer agents targeting other cell surface markers and intracellular signaling pathways are at various stages of preclinical and clinical development (Figure 1)¹⁷⁻¹⁹. Below, we will provide an agent-by-agent review of their effects on Treg maintenance, induction, and function in preclinical models and in clinical settings.

Impact of approved immunosuppressive drugs on Treg

Anti-thymocyte globulin

Rabbit anti-thymocyte globulin (rATG, Thymoglobulin) is used as an induction therapy in patients with high immunologic risk, to permit delayed introduction of CNI, or to treat steroid-refractory acute cell-mediated rejection²⁰. rATG is a polyclonal preparation from rabbits immunized with human thymocytes and has broad specificity against multiple antigens expressed by thymocytes. It depletes CD4⁺ and CD8⁺ T cells for many months, with CD8⁺ T cells recovering more rapidly and completely than CD4⁺ T cells²¹. Mechanisms of ATG mediated immunosuppression include apoptosis and induction of T-cell anergy at low doses, antibody-dependent cellular cytotoxicity (ADCC) at moderate doses, and complement-mediated lymphocyte lysis at high doses²²⁻²⁵. At clinical doses of 1 - 2 mg/kg/day, ADCC is likely to be the primary mechanism while lymphocyte lysis occurs at supra-therapeutic dosage (up to 3.5 mg/kg/day). ATG induction of apoptosis depends on IL-2, which would be limited by concomitant use of medications that inhibit IL-2 or its receptor²²⁻²⁴. ATG may further act to inhibit endothelial adhesion and to deplete lymphocyte reservoirs in peripheral lymph nodes^{23,26,27}.

Treatment of human peripheral blood lymphocytes with low-dose ATG in vitro induces expression of CD25 and FOXP3 in CD4⁺CD25⁻ cells, although whether these in vitro stimulated cells acquire immunosuppressive properties seems context dependent²⁸⁻³¹. ATG induction therapy in vivo reduces the absolute number of Treg, but less than that for Tconvs,

favorably altering the Treg/Tconv ratio^{29,32,33}. Furthermore, Treg recover faster during immune reconstitution following ATG treatment, contributing to the sustained elevation of Treg/Tconv ratio³⁴. However, high-dose ATG impairs thymic generation of Tconv and Treg cells in allogeneic hematopoietic stem cell transplantation^{34,35}. ATG therapy may also modulate antigen-specific immune responses by inducing memory-like Treg, as well as other protective T cells such as Th2 and IL-10-producing Tr1 cells³⁶. Thus, immunological impact of ATG is not only limited to T cell depletion, but also in relative preservation of Treg especially at lower doses.

Anti-CD25 mAb

Anti-CD25 mAb basiliximab and daclizumab are widely used induction agent after solid organ transplantation. Basiliximab is a chimeric mouse-human IgG1 antibody and daclizumab is a humanized IgG1 antibody, both of which block the IL-2-binding site of CD25³⁷⁻⁴⁰. Anti-CD25 mAb were originally developed to suppress immune response by targeting recently activated effector T cells that express CD25. Anti-CD25 mAb can also inhibit activation of CD25⁻ T cells by blocking CD25⁺ dendritic cells from trans-presentation of IL-2 (a process of donating CD25 complexed IL-2)⁴¹. Other CD25⁺ proinflammatory cell types, such as lymphoid tissue-inducer cells and innate lymphocytes⁴², are reduced following daclizumab treatment during multiple sclerosis (MS) flares^{43,44}. These immunosuppressive mechanisms may contribute to the positive clinical outcomes of anti-CD25 mAb in MS^{37,45,46}.

Treatment with basiliximab in transplant patients can lead to a transient reduction of both Treg⁴⁷⁻⁴⁹ and down-modulation of CD25 expression on Treg without deleting the cells or impairing their functions^{50,51,52}. A recent study finds that donor-reactive Treg is minimally impacted in lung transplant patients after basiliximab induction⁵³. Treg normally express low levels of the IL-7 receptor α chain CD127^{54,55}. In MS patients, CD25^{lo} Treg are able to increase CD127 expression and IL-7 responsiveness following daclizumab treatment, explaining Treg rescue in the absence of IL-2 signaling⁵⁶. Moreover, daclizumab increase CD56^{hi} NK cells by increasing the bioavailability of IL-2. These CD56^{hi} NK cells suppress immune responses by killing autologous activated T cells or allogeneic antigen presenting cells^{40,43,56-59}. Overall, anti-CD25 induction inhibits effector T cells and its effect on Treg appears to be transient and of uncertain clinical significance. Anti-CD25 mAb may also promote Treg-independent tolerogenic mechanisms that may offset anti-CD25 mAb impairment of Treg.

Anti-CD52 mAb

Alemtuzumab (CAMPATH-1H, Genzyme) targets CD52 that is highly expressed on T cells and B cells^{60,61}. Although alemtuzumab gained FDA approval for the treatment of leukemia, it has found off-label efficacy as an induction agent in transplantation due to its profound depletion of T and B cells⁶²⁻⁶⁵. The mechanisms of action and effects of alemtuzumab are quite similar to those reported for ATG. ADCC and complement activation via anti-CD52 are the most likely mechanisms for alemtuzumab-mediated killing of CD52⁺ cells, with cell death proportional to surface expression of CD52^{60,66-69}. Alemtuzumab preferentially depletes activated Tconvs over Treg, resulting in a transient elevation of the Treg to Tconv

ratio⁷⁰⁻⁷³. Alemtuzumab can induce conversion of Tconv into Treg⁷³⁻⁷⁵, increase anti-inflammatory cytokines IL-4, IL-10 and TGF- β , and suppress proinflammatory cytokines IFN- γ and IL-17⁷⁶.

CD52 is shed from the cell surface through a phospholipase C-dependent mechanism⁷⁷. Soluble CD52 (sCD52) prevents T cell activation via binding to the inhibitory molecule sialic acid-binding immunoglobulin-like lectins-10 (Siglec-10) on activated T cells^{77,78}. Addition of sCD52 to activated Tconvs in vitro inhibits T cell proliferation through a Siglec-10 dependent mechanism⁷⁸⁻⁸⁰. sCD52 also prevents leukocyte adhesion to vascular endothelium by blocking Siglec-10 interaction with vascular adhesion protein-1, further modulating the local immune response⁸¹. These findings suggest immune regulatory functions for sCD52 protein, which may also be blocked by alemtuzumab.

CNI

CNIs, tacrolimus (FK506) and cyclosporine (Cyclosporin A, CsA), are the most commonly used drugs for maintenance immunosuppression following solid organ transplantation⁸². They act by inhibiting the intracellular phosphatase calcineurin, which dephosphorylates cytosolic nuclear factor of activated T cells (NFAT) to allow for its nuclear translocation and transcriptional activation of cytokine genes such as IL-2^{83,84}. IL-2 is a regulator of proliferation, survival, and maturation for all T cell subtypes, including Treg⁸⁵. While the function of IL-2 on Tconvs can be substituted by other cytokines, IL-2 is indispensable for Treg development, homeostasis, and function⁸⁶.

CNIs impair Treg by directly inhibiting Treg activation, inhibiting the generation of pTreg, and indirectly by limiting IL-2 production by Tconvs. CNIs inhibit Treg proliferation in a dose-dependent fashion in vitro⁸⁷. The FOXP3 promoter and enhancers contain multiple NFAT binding sites. NFAT binding to the CNS1 enhancer is important to pTreg induction⁸⁸ and its binding to CNS2 enhancer is critical for Treg stability⁸⁹⁻⁹¹. Decreased FOXP3 mRNA expression in Treg exposed to cyclosporine correlates with reduced suppressor activity⁹². Treatment with tacrolimus also increases FOXP3⁺ TSDR-demethylated “ex-Treg”, suggesting that CNIs may transform Treg into Tconvs^{91,93}.

The effects of CNIs on Treg are dose and duration dependent. High-dose, but not low-dose, CNI exposure alters gene expression in Treg⁸⁷. A portion of NFAT constitutively resides in the nucleus of most Treg, making Treg resistant to short-term low-dose action of CNIs⁹⁴⁻⁹⁷. CNIs also indirectly affect Treg by inhibiting IL-2 expression from Tconvs. The decrease of FOXP3 expression in Treg by cyclosporine is restored by addition of IL-2^{92,98}. Combining IL-2 with CsA resulted in an increase of Treg by permitting IL-2-induced Treg expansion and function while preventing antigen-specific Tconv proliferation in vivo⁹⁸. These studies suggest that a combination of low-dose CNIs and low-dose IL-2 may achieve the desired effect of selectively inhibiting Tconvs while sparing Treg. A recent report in nonhuman primates demonstrates that IL-2 therapy broke kidney allograft tolerance induced by mixed bone marrow chimerism despite an increase in Treg⁹⁹. Breaking tolerance in this study was IL-2 dose dependent and required a lower dose in primates with lymphoid aggregates in the allografts than in those with pristine grafts. In comparison, following autologous stem-cell transplantation, low-dose IL-2 therapy was found to be effective in promoting Treg and

ameliorating GvHD¹⁰⁰⁻¹⁰². The disparities in these findings may be rooted in the dose of IL-2 used and the immunological status of the recipients. None of these studies evaluated the concurrent use of CNI with low-dose IL-2 as an approach to reduce impairment of Treg by CNI.

Current clinical trials are exploring CNI-sparing protocols to minimize nephrotoxicity of CNIs¹⁰³. Although the data are promising for restoration of Treg, some patients need to resume CNIs because of rejection. As a result, the OPTN/SRTR Annual Data Report in 2013 recommend against CNI withdrawal⁸². The finding that Treg are resistant to low-dose CNI and combining CNIs with sirolimus restore Treg^{93,104} suggest that reducing CNI dose may not only spare patients from the nephrotoxicity, but also spare Treg.

Mycophenolate

Mycophenolate Mofetil (MMF) is a mainstay of immunosuppression regimens in transplantation, typically in combination with CNI and prednisone. Following in vivo conversion to its active form of mycophenolic acid, MMF inhibits de novo purine synthesis by blocking the enzyme inosine monophosphate dehydrogenase (IMPDH)¹⁰⁵. B cells and T cells are dependent on this pathway for proliferation, because they cannot bypass this requirement using the salvage pathway of purine biosynthesis¹⁰⁶. Additionally, the type II isoform of IMPDH, found in activated T and B cells, is 5 times more sensitive to mycophenolic acid than the type I isoform present in all cells, including resting lymphocytes^{106,107}. MMF may also act by down-regulating costimulatory ligands on dendritic cells, indirectly impairing T cell activation¹⁰⁸. Further mechanisms have implicated MMF in induction of T cell apoptosis, inhibition of IL-1 expression, and impairment of nitric oxide production¹⁰⁶.

Treatment of murine Treg with MMF in vitro does not impair the viability or function of Treg in MLR¹⁰⁹, and treatment of activated human PBMC with MMF does not alter Treg phenotype but inhibits proinflammatory Th1 and Th17 responses¹¹⁰. MMF treatment promotes Treg predominance over Th17 cells by inhibiting T cell Ig mucin-1 expression, a protein that promote differentiation into effector T cells than Treg^{111,112}. However, administration of supra-therapeutic MMF monotherapy to mice receiving Treg cell therapy reduced the efficacy of Treg¹¹³. In liver transplant recipients, conversion from CNI to MMF with a 1-time dose of daclizumab showed an increase in the percentage of Treg from baseline¹¹⁴. Analysis of kidney transplant patients on stable immunosuppression regimens identified higher levels of CD4⁺CD25^{high}FOXP3⁺ Treg in patients receiving MMF versus everolimus¹¹⁵. Overall, preclinical and clinical evidence thus far suggest that MMF is compatible with Treg homeostasis and function.

Corticosteroids

A multitude of anti-inflammatory mechanisms have been attributed to corticosteroids. Corticosteroids bind their cytosolic glucocorticoid receptor, translocate to the nucleus, and inhibit NF- κ B-mediated transcription, resulting in broad suppression of proinflammatory cytokines¹¹⁶⁻¹¹⁸. Glucocorticoids may also bind to specialized receptors on T cells, which uncouple TCR signaling from downstream signal transduction pathways^{118,119}. Extracellular

steroid binding can impair T cell interaction with APCs, down-regulate leukocyte rolling and adhesion, and disrupt the T cell cytoskeleton to inhibit migration^{120,121}. Corticosteroids also alter the balance of T cell subsets to favor a predominance of Th2 cells and Treg^{122,123}.

In a murine model of MS, treatment with dexamethasone and IL-2 expands Treg¹²⁴. Patients treated with glucocorticoids for autoimmune and atopic diseases have likewise demonstrated an increase in Treg percentage amongst T cell subsets^{125,126}. In transplantation, treatment with methylprednisolone during kidney rejection episodes alters T cell composition to favor highly-suppressive DR^{high}CD45RA⁻ Treg¹²⁷. Steroids are able to induce pTreg by promoting the expression of glucocorticoid-induced leucine zipper (GILZ), which facilitates TGF- β signaling and FOXP3 expression¹²⁸. GILZ appears to be a strong inducer of FOXP3⁺ expression, but deletion of GILZ does not completely inhibit FOXP3⁺ expression in Treg, suggesting that glucocorticoids promote Treg through multiple, redundant mechanisms¹²⁹. Overall, corticosteroids likely benefit Treg prevalence and activity. Additionally, steroids may also create a favorable immune environment for Treg through modulation of local cytokine expression.

mTOR Inhibitors

Two mTOR inhibitors are currently FDA approved for transplantation, sirolimus (rapamycin, Rapamune) and everolimus (Zortress). Rapamycin, first identified as a potent antifungal isolated from *Streptomyces hygroscopicus* bacteria, was also found to have immunosuppressive capabilities by inhibiting the serine/threonine kinase mTOR downstream of phosphatidylinositol 3-kinase (PI3K) and Akt^{130,131}. mTOR acts through 2 distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Rapamycin is more effective at inhibiting mTORC1, and is able to inhibit mTORC2 only after prolonged exposure¹³²⁻¹³⁴. The 2 mTOR complexes mediate distinct cellular activities. Th1 and Th17 differentiation of CD4⁺ T cells are dependent on mTORC1, whereas Th2 differentiation requires mTORC2¹³⁵. However, both mTOR complexes promote glycolytic metabolism in CD8⁺ T cells and drive effector CD8⁺ T cell differentiation at the expense of memory CD8⁺ T cell formation¹³⁶. Thus, mTOR deficiency or rapamycin treatment inhibits CD8⁺ effectors but paradoxically enhances CD8⁺ T cell memory response¹³⁷.

The PI3K-Akt-mTOR signaling axis critically controls Treg development, homeostasis and function¹³⁸. Activation of CD4⁺ Tconvs while blocking PI3K, Akt, or mTOR signaling leads to Treg induction in vitro¹³⁹. In committed Treg, this signaling axis is suppressed by high expression of PTEN, an intracellular phosphatase that inhibits PI3K-Akt-mTOR signaling. Excessive activation of this axis, as seen in PTEN-deficient Treg, leads to Treg destabilization due to mTORC2 over activation^{140,141}. Treg alternatively employ the kinase PIM2 for cell growth and activation¹⁴², and as a result, Treg are able to proliferate in the presence of rapamycin¹⁴³⁻¹⁴⁵. This property of rapamycin has been exploited for manufacturing Treg for therapeutic applications. Addition of rapamycin in Treg expansion cultures inhibits Tconv outgrowth while preserving Treg identity, yielding purer and more potent cellular products¹⁴⁶. In kidney transplant recipients, patients on sirolimus maintenance immunosuppression show a 4-fold increase in circulating Treg when compared to patients receiving cyclosporine¹⁴⁷. Additionally, converting from CNIs to a rapamycin-

based regimen produces a sustained increase in peripheral Treg for months following conversion^{93,104}. However, this increased proportion of Treg failed to correlate to significant improvement in clinical outcomes, with a mild protective benefit in GFR but no significant difference in rejection, graft loss, or development of neoplasm¹⁴⁷⁻¹⁴⁹. It is worth noting that rapamycin does not promote Treg expansion, and the enrichment of Treg seen *in vitro* and *in vivo* by rapamycin is due a higher sensitivity of Tconv to rapamycin than Treg. Treg resistance to mTOR inhibition is not absolute. In fact, addition of rapamycin to *ex vivo* Treg cultures dramatically reduces Treg proliferation, but less so than it inhibits Tconv proliferation¹⁴⁶. Selective deletion of mTORC1 in mouse Treg leads to impairment of Treg function and systemic autoimmunity, demonstrating that mTORC1 is required for proper Treg activation¹⁵⁰. Taken together, targeting mTOR may promote pTreg induction and selectively suppress Tconvs while sparing Treg. This Treg favoring effect is dose-dependent and high doses of mTOR inhibitors will also negatively impact Treg function.

CTLA4-Ig

Productive T cell activation requires TCR signaling along with costimulation through CD28 interaction with CD80 or CD86 on APCs¹⁸. At the same time, CTLA-4, a CD28 homolog expressed on activated T cells, bind to CD80 and CD86 with high affinity to inhibit T cell activation. CTLA4-Igs are genetically engineered soluble fusion proteins that bind to CD80 and CD86, thereby inhibiting CD28 costimulation. Two CTLA4-Igs, belatacept and abatacept are currently available; both consist of the extracellular domain of human CTLA4 linked to a modified Fc of human IgG1, with belatacept containing modifications to increase affinity for CD80 and CD86. Currently, belatacept is FDA approved as an immunosuppressant for kidney transplantation¹⁵¹.

While CD28 costimulation is critical for Tconv activation, it is also essential for tTreg development and homeostasis¹⁵². CD28-deficient mice have reduction in Treg leading to exacerbated autoimmune diseases in autoimmune-prone mice¹⁵²⁻¹⁵⁴. Effector T cell activation requires higher CD80 and CD86 expression than is needed for maintaining Treg homeostasis; thus, partial CD80 and CD86 blockade prevents the emergence of effector T cells while permitting Treg homeostasis in mouse models and in kidney transplant patients^{47,155}. Moreover, while complete absence of CD80 and CD86 abrogate pTreg genesis, strong costimulation through CD28 drives effector T cell programming at the expense of pTreg induction. Thus, partial CD80 and CD86 blockade using CTLA4-Ig may favor pTreg development¹⁵⁶. CTLA4-Ig may also operate independently of blocking CD28 signaling by inducing dendritic cell expression of indoleamine 2,3-dioxygenase, leading to tryptophan catabolism, T cell apoptosis, and activation of Treg^{157,158}. CTLA4-Ig is shown to promote nitric oxide production by macrophages, contributing to Treg generation while inhibiting proinflammatory cytokines¹⁵⁹⁻¹⁶¹. Long-term clinical follow-up of kidney transplant patients treated with belatacept demonstrates superior graft function at 5 years without differences in graft or patient survival when compared to CNI-based immunosuppression^{162,163}. Studies in liver transplantation are less encouraging¹⁶⁴ and CTLA4-Ig has not been well studied in other solid organ transplants. Overall, CTLA4-Ig is compatible with Treg function at the right dose and can be an effective replacement for CNI at thwarting rejection with minimal renal toxicity.

Impact of alternative immunosuppressive agents on Treg

Anti-CD20 mAb

Rituximab is an anti-CD20 mAb that depletes B cells, most frequently used in transplantation for management of antibody-mediated rejection and ABO-incompatible kidney transplants¹⁶⁵. Current data investigating the impact of rituximab on Treg are mostly derived from autoimmune models, with somewhat conflicting results. B cell depletion with rituximab in a mouse model of arthritis correlated with increases in Treg number and function¹⁶⁶. Similarly, patients with systemic lupus erythematosus showed an increase in the percentage of CD4⁺CD25^{bright} Treg with rituximab treatment^{167,168}. However, another report showed that B cells were critical for maintenance of Treg in autoimmune disease¹⁶⁹. Within the transplant population, a study evaluated the addition of rituximab induction to standard immunosuppression in renal transplantation and revealed no detrimental effect on Treg¹⁷⁰. Rituximab may have further use in the transplant population, as it has shown efficacy in both prophylaxis against acute GVHD and treatment of steroid-refractory chronic GVHD in allogeneic stem cell transplant patients, which is believed to be a B cell-dependent process¹⁷¹⁻¹⁷³. More studies within the transplant population are needed to better understand the effects of B cell depletion on Treg^{167,174-176}.

LFA-3 Fusion Protein

Alefacept (Amevive, Astella Pharma) is a fusion protein of LFA-3 and human IgG1 to target CD2 that is highly expressed on memory T cells. Alefacept prevents T cell activation by blocking CD2-mediated costimulation and enhances NK cell-mediated lysis of CD2-expressing cells. Alefacept use led to selective loss of CD40RO⁺ memory T cells without affecting native T cells in psoriasis patients¹⁷⁷. In a more recent phase II trial in patients with type 1 diabetes, alefacept was found to spare Treg, leading to an increased ratio of Treg to memory T cells¹⁷⁸. Alefacept prolonged kidney allograft survival in nonhuman primates when combined with abatacept by targeting CD28⁻ effector T cells^{179,180}. However, 2 follow-up studies in nonhuman primates using an optimized immunosuppressive regimen of belatacept and intramuscular sirolimus found that addition of alefacept conferred no benefit in graft survival and increased risk of opportunistic infections^{181,182}. Moreover, dramatic reduction in the frequency of Treg was observed in monkeys that received additional alefacept. These studies used a higher dose of alefacept than previous studies in addition to the optimized concurrent immunosuppressions. These dosing differences may explain the distinct efficacy outcomes and discordant findings with respect to Treg. In human transplant patients, addition of alefacept to the standard immunosuppressive regimen of tacrolimus, MMF, and corticosteroids was well tolerated, but did not reduce acute rejection rates¹⁸³. Unfortunately, this study did not report the impact of supplemental alefacept on Treg. Since memory T cells pose a significant threat to transplanted grafts, preservation of Treg while reducing memory T cells is a highly desirable goal for optimizing immunosuppression in transplant patients. Future studies are needed to determine if alefacept could benefit patients with higher immunological risks such as those with autoimmune diseases, HIV infections, or those prone to rejection on a belatacept-based regimen.

JAK3 Inhibitors

Janus associated kinase 3 (JAK3) transduces signals downstream of CD132, which is the common gamma chain shared among many cytokine receptors including receptors for IL-2^{184,185}. JAK3 signaling is critical to normal homeostasis and function of T cells, B cells, and NK cells. The importance of JAK3 to normal immune function is demonstrated by the severe combined immunodeficiency in patients with inborn JAK3 mutations^{184,186}. Thus, JAK3 inhibitors such as tofacitinib (Xeljanz, Pfizer) can broadly affect many immune cells including various CD4⁺ T helper subsets, CD8⁺ T cells, NK cells, as well as Treg. Although mouse studies of JAK3 inhibitors have shown preservation of Treg, JAK3 inhibitor use at 30 mg twice daily in transplant patients partially depletes CD4⁺CD25^{bright} Treg¹⁸⁷. Early clinical trials in kidney transplant patients found that this dose of tofacitinib led to a trend toward higher rejection and increased infections, whereas 15 mg twice daily was comparable to CNI in incidences of rejection and infections¹⁸⁸. However, the impact of low-dose tofacitinib on Treg and other immune cells was not reported. An in vitro analysis of tofacitinib inhibition of STAT5 phosphorylation showed that CD25^{-dim} T cells were nearly twice as susceptible to JAK3 inhibition as CD4⁺CD25^{bright} T cells, suggesting that lower doses of tofacitinib may preferentially inhibit Tconvs that have lower expression of CD25¹⁸⁹.

Anti-LFA-1 Antibodies

Leukocyte function antigen-1 (LFA-1) is a cell surface adhesion molecule expressed on a variety of leukocytes that controls leukocyte transmigration from blood to peripheral tissues¹⁹⁰. In T cells, LFA-1 is also essential for the establishment of an immunologic synapse between T cells and APCs. Similar to CD2 described above, LFA-1 expression is higher on memory T cells than on naïve T cells. Anti-LFA-1 antibodies (efalizumab; Raptiva, Genentech) impair the stimulatory interaction of naïve and memory T cells. The addition of efalizumab to full-dose CNI maintenance therapy led to profound immunosuppression and increased incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients¹⁹¹. On the other hand, efalizumab allowed reduction of CNI dosing by half without increasing rejection. In islet transplantation, a combination of ATG induction and efalizumab-based maintenance immunosuppression allowed patients to achieve insulin independence on a steroid-free CNI-free regimen¹⁹². Surprisingly, this regimen also led to a dramatic rise of the percentage of Treg to 30 to 70% among circulating CD4⁺ T cells in all study participants¹⁹². This finding suggests that efalizumab differentially affects Treg versus Tconv homeostasis and/or trafficking. Efalizumab was withdrawn from market because of incidences of serious infections in psoriasis patients. However, the use of efalizumab in transplantation, particularly as an induction agent, warrants further exploration.

Anti-IL-6R mAb

IL-6 is produced early by a wide variety of immune and nonimmune cells in response to acute injury and elicits its cellular actions by binding to IL-6R. IL-6R dimerizes with a transmembrane protein gp130, which is responsible for transmitting intracellular signals. IL-6R can shed from the membrane generating a soluble form of the receptor (sIL-6R) that

can complex with IL-6 and activate cells that lack the membrane-bound IL-6R but express gp130. This “trans-signaling” process is known to be important in the transition from acute to chronic phases of inflammation¹⁹³. IL-6 has pleiotropic effects including granulopoiesis, B cell growth and maturation, and T cell proliferation and differentiation. Notably, IL-6 occupies a unique position in determining the fate of naïve T cells. In the presence of IL-6, TGF- β drives naïve T cells into proinflammatory Th17 cells, whereas in the absence of IL-6, TGF- β induces pTreg¹⁹⁴. In addition, IL-6 renders Tconv resistant to Treg suppression and directly destabilizes Treg by inhibiting FOXP3 expression¹⁹⁵⁻¹⁹⁷. IL-6 has been implicated in frailty, which is an emerging risk factor for poor transplant outcomes^{198,199}. Thus, IL-6 critically regulates Treg number and function, and the level of IL-6 in patients may impact to transplant outcomes.

Tocilizumab (Actemra) is a recombinant humanized anti-IL-6R monoclonal IgG1 antibody that prevents IL-6 from binding to membrane-bound and soluble IL-6R. Tocilizumab is currently FDA-approved for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Tocilizumab treatment leads to a significant and sustained increase in the proportion of Treg in patients with rheumatoid arthritis^{200,201}. In transplantation, blocking IL-6 leads to decreased IFN- γ and IL-17 mRNA, reduced alloantigen-stimulated T cell proliferation, increased proportion of Treg, and prolonged allograft survival in mouse models²⁰²⁻²⁰⁴. In humans, IL-6 is associated with acute and chronic rejections and IL-6 levels correlate with the degree of inflammation in the allografts²⁰⁵⁻²¹⁰. The use of tocilizumab with intravenous immunoglobulin in sensitized kidney transplant patients shows improved donor-specific antibody levels similar to the results obtained in a mouse model^{211,212}. Together, anti-IL-6R has multiple anti-inflammatory properties and may favor the function and stability of Treg. Future studies are needed to determine the effects of tocilizumab on Treg in transplant patients.

Anti-CD28 Antibodies

CTLA-4Ig blocks CD80- and CD86-mediated costimulation through CD28 but also blocks CTLA-4 engagement with CD80 and CD86 and CD80 with to PDL-1^{213,214}. Blockade of T cell checkpoints CTLA-4 and PD-1 is a major breakthrough in cancer treatment, which underscores the importance of these pathways in immune regulation²¹⁵. Anti-CTLA-4 and anti-PD-1 therapies in transplant recipients with metastatic melanoma provide insights on how these pathways contribute to alloimmune responses. So far, 5 published reports described 6 cases of kidney or liver transplant recipients receiving checkpoint blockade. Four patients (2 liver and 2 kidney recipients) received anti-CLTA-4, with all 4 showing tumor regression without long-term impairment of graft function²¹⁶⁻²¹⁸. One kidney transplant recipient showed tumor regression with anti-PD-1 therapy, but lost kidney graft to acute cellular rejection²¹⁹. One kidney transplant recipient received initial anti-CTLA-4 therapy without rejection or tumor regression, but follow-up anti-PD-1 therapy precipitated graft rejection while inducing tumor shrinkage²²⁰. These early experiences suggest that PD-1, but not CTLA-4, may be crucial in suppressing alloreactive T cells in patients with stable graft function. Nonetheless, blockade of CD28 using anti-CD28 mAbs more specifically targets the immune activation function of this complex network of activators and inhibitors. However, many anti-CD28 mAbs have agonist activities. Although agonist anti-

CD28 mAbs in rodents show preferential augmentation of Treg and therapeutic efficacy in autoimmune diseases, an early human trial revealed life-threatening cytokine storm in healthy volunteers after receiving agonist anti-CD28 mAb²²¹. Monovalent anti-CD28 Fab lacking an Fc region abrogates agonist activity and effectively blocks T cell activation²²²⁻²²⁶. When evaluated in animal models of organ transplantation, monovalent anti-CD28 mAbs are able to protect allografts from acute and chronic rejection while increasing the proportion of peripheral CD4⁺Foxp3⁺ Treg^{223,225,227}. These favorable pre-clinical findings has led to an ongoing phase I trial in healthy subjects to define the safety and tolerability of this therapy in humans with potential future development in transplantation and autoimmune diseases.

Inhibitors of TNF family ligands and their receptors

TNF family ligands, such as TNF α , CD40L, OX40L, and 41BBL, are primarily proinflammatory by promoting activation of both innate and adaptive immunity. Each member and their respective receptors are all potential targets for immune modulation. We will briefly summarize preclinical and clinical experiences of antagonists targeting 3 members of the TNF family that have been most studied in the context of transplantation.

Anti-TNF α mAb infliximab (Remicade, Janssen Biotech) is able to down-regulate proinflammatory cytokines in a number of autoimmune diseases, and its use has been shown to increase functional Treg in RA patients²²⁸⁻²³⁰. Induction therapy containing anti-TNF α and T cell depleting agents in clinical islet transplantation leads to higher rate of insulin independence when compared to anti-CD25-based induction²³¹.

CD40 and CD40L have critical functions in regulating T and B cell function, through their co-stimulatory interaction in the activation of naïve T cells and induction of high affinity antibody production. In the non-obese diabetic mouse model, CD40L deficiency impairs effector T cell function without impacting Treg, and stimulation through CD40 on APC rendered the cells resistant to Treg-mediated suppression^{232,233}. These findings suggest that targeting the CD40/CD40L interaction may selectively block effector cell differentiation while preserving function of Treg. Indeed, CD40L blockade showed remarkable efficacy in promoting allograft tolerance in murine and non-human primate models. Clinical translation of this strategy was halted due to a high incidence of thromboembolism²³⁴. Since thrombus stabilization by anti-CD40L is dependent on Fc receptor binding and mediated by CD40L binding to beta 3 integrin, not CD40, alternative strategies using anti-CD40L and CD40-targeting antibodies which bypass Fc receptor binding are being evaluated in preclinical and early clinical trials²³⁵⁻²³⁹.

OX40L is constitutively expressed by Treg and induced on Tconvs after activation. Blocking antibodies to OX40L inhibit memory T cell function and allow for Treg expansion in murine cardiac allograft models^{240,241}. Costimulation through OX40L abrogates conversion of Tconv to Treg in vitro whereas OX40L synergizes with IL-2 to induce proliferation of Treg that have already developed. OX40 stimulation alone induces moderate Treg proliferation but down-regulates FOXP3 expression and increases expression of PD-1²⁴²⁻²⁴⁴. Addition of IL-2 to OX40L induced more robust Treg proliferation while maintaining high FOXP3

expression. In transplant patients on CNI when IL-2 availability may be reduced, inhibition of OX40L may prevent destabilization of formed Treg and promote pTreg generation.

Vitamin D

Although not normally considered an immunosuppressant, vitamin D has potent immune modulatory activities on many cells types²⁴⁵. Conversion of Vitamin D into its biologically active form 1,25-OH vitamin D₃ starts in the skin and completes in the kidney by renal tubule cells. Macrophages are also capable of producing vitamin D₃ from its precursors, providing a local source of vitamin D₃ at site of immune activation. Vitamin D₃ is anti-inflammatory and promotes immune regulation via IL-10 and Treg induction. The immunologic effects of vitamin D deficiency in the kidney transplant population – where end-stage renal disease leads to dysregulation of vitamin D metabolism – can persist well beyond successful transplantation of a renal allograft. Low vitamin D levels are predictive for deterioration in allograft glomerular filtration rate^{246,247} and correlate with acute rejection, infection, and mortality in lung transplant patients²⁴⁸. Given the potentially significant immunologic impact of vitamin D deficiency and the safety of vitamin D supplementation, normalization of vitamin D levels should be recommended in the transplant population.

Conclusion

Modifying immunosuppression regimens to selectively inhibit effector and memory T cells while permitting Treg development, survival, and function could theoretically allow for minimization of immunosuppressive drugs and favor tolerance induction. Current knowledge of Treg biology reveals numerous distinctions between Treg and Tconvs that may be targeted therapeutically to favor Treg (Figure 2). Many of these distinctions, such as IL-2 responsiveness, CD28 and mTOR dependence, CNI sensitivity, and resistance to lymphodepletion are not absolute but quantitative. Thus, selection of Treg-friendly immunosuppressive regimens not only has to consider which drugs to use, but also what dose to apply. Many immunosuppressive drugs currently used in transplant patients are compatible with Treg at lower doses. It is possible that a combination of multiple immunosuppressants at low-dose would be better able to support Treg while adequately preventing rejection while minimizing toxicity. When evaluating new immunosuppressive regimens, close monitoring of the numbers, activation status, and function of Tconvs versus Treg, in addition to clinical outcomes, will help to enrich our knowledge and guide future development of tolerogenic therapies for transplantation. It is important to note that the high proportion of Treg needed to induce transplant tolerance in preclinical models²⁴⁹ is not likely achievable by titrating doses of immunosuppressive drugs alone. Combining Treg cell therapy, attenuation of effector responses, and Treg-supportive immunosuppression may be needed to induce tolerance.

Acknowledgments

The authors thank Dr. John R. Greenland for his helpful comments on the manuscript.

Funding: The efforts of QT on this work are supported by NIH grants 1U01AI110658, 1U01 AI113362-01, and 1U01AI104347. SW is a recipient of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research Fellowship.

Abbreviations

ADCC	antigen dependent cellular cytotoxicity
APC	antigen presenting cell
ATG	anti-thymocyte globulin
CNI	calcineurin inhibitor
CsA	cyclosporine
GILZ	glucocorticoid-induced leucine zipper
GVHD	graft-versus-host disease
IMPDH	inosine monophosphate dehydrogenase
JAK	Janus-associated kinase
LFA	lymphocyte function-associated antigen
mAb	monoclonal antibody
MLR	mixed lymphocyte reaction
MMF	mycophenolate mofetil
MS	multiple sclerosis
NFAT	nuclear factor of activated T cells
mTOR	mammalian Target of Rapamycin
mTORC	mTOR complex
PI3K	phosphatidylinositol 3-kinase
RA	rheumatoid arthritis
Siglec-10	sialic acid-binding immunoglobulin-like lectins-10
TAC	tacrolimus
Tconv	conventional T cell
TCR	T cell receptor
Teff	effector T cell
TGF-β	transforming growth factor- β
Treg	regulatory T cells

TSDR Treg-specific demethylated region

References

1. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. *Nat Immunol.* 2008; 9(3):239–244. [PubMed: 18285775]
2. Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: moving to the clinic. *Cold Spring Harb Perspect Med.* 2013; 3(11)
3. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. *Immunity.* 2013; 38(3):414–423. [PubMed: 23521883]
4. Liu ZM, Wang KP, Ma J, Guo Zheng S. The role of all-trans retinoic acid in the biology of Foxp3(+) regulatory T cells. *Cell Mol Immunol.* 2015; 12(5):553–557. [PubMed: 25640656]
5. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. *J Immunol.* 2010; 184(7):3433–3441. [PubMed: 20181882]
6. Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. *J Exp Med.* 2012; 209(10):1713–1722. S1711–1719. [PubMed: 22966003]
7. Haribhai D, Williams JB, Jia S, et al. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. *Immunity.* 2011; 35(1):109–122. [PubMed: 21723159]
8. Kim HJ, Barnitz RA, Kreslavsky T, et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. *Science.* 2015; 350(6258):334–339. [PubMed: 26472910]
9. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK. Helios+ and Helios– cells coexist within the natural FOXP3+ T regulatory cell subset in humans. *J Immunol.* 2013; 190(5): 2001–2008. [PubMed: 23359504]
10. Lee HM, Bautista JL, Hsieh CS. Thymic and peripheral differentiation of regulatory T cells. *Adv Immunol.* 2011; 112:25–71. [PubMed: 22118406]
11. Yu A, Snowwhite I, Vendrame F, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. *Diabetes.* Jun; 2015 64(6):2172–2183. [PubMed: 25576057]
12. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? *Int Immunol.* 2009; 21(10):1105–1111. [PubMed: 19737784]
13. Yuan X, Dee MJ, Altman NH, Malek TR. IL-2Rbeta-dependent signaling and CD103 functionally cooperate to maintain tolerance in the gut mucosa. *J Immunol.* 2015; 194(3):1334–1346. [PubMed: 25527788]
14. Cobbold SP, Waldmann H. Regulatory cells and transplantation tolerance. *Cold Spring Harb Perspect Med.* 2013; 3(6)
15. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. *N Engl J Med.* 2010; 363(15):1451–1462. [PubMed: 20925547]
16. Lowenberg M, Stahn C, Hommes DW, Buttgerit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. *Steroids.* 2008; 73(9-10):1025–1029. [PubMed: 18221974]
17. Gardner D, Jeffery LE, Sansom DM. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. *Am J Transplant.* 2014; 14(9):1985–1991. [PubMed: 25098238]
18. Halloran PF. Immunosuppressive drugs for kidney transplantation. *N Engl J Med.* 2004; 351(26): 2715–2729. [PubMed: 15616206]
19. Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. *Transplantation.* 2014; 98(3): 312–319. [PubMed: 24770617]

20. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. *Drugs*. 2010; 70(6):691–732. [PubMed: 20394456]
21. Grafals M, Smith B, Murakami N, et al. Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. *PLoS One*. 2014; 9(8):e104408. [PubMed: 25111080]
22. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. *Blood*. 1998; 91(7):2360–2368. [PubMed: 9516135]
23. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. *Transplantation*. 2001; 71(3):460–468. [PubMed: 11233911]
24. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. *Transplantation*. 1998; 65(11):1481–1489. [PubMed: 9645807]
25. Mourad G, Morelon E, Noel C, Glotz D, Lebranchu Y. The role of Thymoglobulin induction in kidney transplantation: an update. *Clin Transplant*. 2012; 26(5):E450–464. [PubMed: 23061755]
26. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. *Transplantation*. 2003; 75(5):657–662. [PubMed: 12640305]
27. Chappell D, Beiras-Fernandez A, Hammer C, Thein E. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. *Transplantation*. 2006; 81(4):552–558. [PubMed: 16495803]
28. Shimony O, Nagler A, Gellman YN, et al. Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. *J Clin Immunol*. 2012; 32(1): 173–188. [PubMed: 21979414]
29. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. *J Am Soc Nephrol*. 2006; 17(10):2844–2853. [PubMed: 16914538]
30. Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. *Blood*. 2008; 111(7):3675–3683. [PubMed: 18250226]
31. Broady R, Yu J, Levings MK. ATG-induced expression of FOXP3 in human CD4(+) T cells in vitro is associated with T-cell activation and not the induction of FOXP3(+) T regulatory cells. *Blood*. 2009; 114(24):5003–5006. [PubMed: 19822903]
32. Tang Q, Leung J, Melli K, et al. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. *Transpl Int*. 2012; 25(12):1257–1267. [PubMed: 22994802]
33. D'Addio F, Yuan X, Habicht A, et al. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. *Transplantation*. 2010; 90(3):260–269. [PubMed: 20712076]
34. Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. *Am J Transplant*. 2010; 10(9):2132–2141. [PubMed: 20883548]
35. Na IK, Wittenbecher F, Dziubianau M, et al. Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. *Haematologica*. 2013; 98(1):23–30. [PubMed: 22801968]
36. Xia CQ, Chernatynskaya AV, Wasserfall CH, et al. Anti-thymocyte globulin (ATG) differentially depletes naive and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice. *BMC Immunol*. 2012; 13:70. [PubMed: 23237483]
37. Pascual J, Marcen R, Ortuno J. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. *Nephrol Dial Transplant*. 2001; 16(9):1756–1760. [PubMed: 11522853]
38. Du J, Yang H, Zhang D, et al. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. *J Immunol*. 2010; 184(3):1361–1368. [PubMed: 20032294]

39. Yang H, Wang J, Du J, et al. Structural basis of immunosuppression by the therapeutic antibody daclizumab. *Cell Res.* 2010; 20(12):1361–1371. [PubMed: 20820193]
40. Wiendl H, Gross CC. Modulation of IL-2R α with daclizumab for treatment of multiple sclerosis. *Nat Rev Neurol.* 2013; 9(7):394–404. [PubMed: 23732529]
41. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. *Nat Med.* 2011; 17(5):604–609. [PubMed: 21532597]
42. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells--a proposal for uniform nomenclature. *Nat Rev Immunol.* Feb; 2013 13(2):145–149. [PubMed: 23348417]
43. Lin YC, Winokur P, Blake A, Wu T, Romm E, Bielekova B. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. *Ann Clin Transl Neurol.* May; 2015 2(5):445–455. [PubMed: 26000318]
44. Perry JS, Han S, Xu Q, et al. Inhibition of LT α cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. *Sci Transl Med.* 2012; 4(145):145ra106.
45. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. *Transplantation.* 2004; 77(2):166–176. [PubMed: 14742976]
46. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. *Transplantation.* 2001; 72(5):839–845. [PubMed: 11571447]
47. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. *Am J Transplant.* Oct; 2008 8(10):2086–2096. [PubMed: 18828769]
48. Bouvy AP, Klepper M, Kho MM, et al. The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients. *Nephrol Dial Transplant.* 2014; 29(8):1587–1597. [PubMed: 24771499]
49. Zhao T, Yang C, Xue Y, et al. Impact of basiliximab on the proportion of regulatory T cells and their subsets early after renal transplantation: a preliminary report. *Transplant Proc.* 2012; 44(1):175–178. [PubMed: 22310608]
50. Krystufkova E, Sekerkova A, Striz I, Brabcova I, Girmanova E, Viklicky O. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. *Nephrol Dial Transplant.* 2012; 27(6):2576–2582. [PubMed: 22167587]
51. Wang Z, Shi BY, Qian YY, Cai M, Wang Q. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. *Clin Exp Immunol.* 2009; 155(3):496–503. [PubMed: 19141125]
52. Vondran FW, Timrott K, Tross J, et al. Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. *Transpl Int.* 2010; 23(5):514–523. [PubMed: 19951265]
53. Greenland JR, Wong CM, Ahuja R, et al. Donor-Reactive Regulatory T-Cell Frequency Increases During Acute Cellular Rejection of Lung Allografts. *Transplantation.* Apr 13.2016
54. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 $^{+}$ T reg cells. *J Exp Med.* Jul 10; 2006 203(7):1701–1711. [PubMed: 16818678]
55. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. *J Exp Med.* 2006; 203(7):1693–1700. [PubMed: 16818676]
56. Martin JF, Perry JS, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. *J Immunol.* 2010; 185(2):1311–1320. [PubMed: 20543101]
57. Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. *J Immunol.* Jul 15; 2011 187(2):781–790. [PubMed: 21666061]

58. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2/alpha-targeted therapy (daclizumab) in multiple sclerosis. *Proc Natl Acad Sci U S A*. 2006; 103(15):5941–5946. [PubMed: 16585503]
59. Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity. *J Immunol*. 2010; 184(5): 2329–2336. [PubMed: 20139277]
60. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. *Immunology*. Oct; 2009 128(2):260–270. [PubMed: 19740383]
61. Coles AJ. Alemtuzumab therapy for multiple sclerosis. *Neurotherapeutics*. Jan; 2013 10(1):29–33. [PubMed: 23184314]
62. Morgan RD, O'Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. *Transplantation*. Jun 27; 2012 93(12): 1179–1188. [PubMed: 22660659]
63. Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. *J Clin Oncol*. 2003; 21(9):1874–1881. [PubMed: 12721266]
64. Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation? *BioDrugs*. 2003; 17(3):147–154. [PubMed: 12749751]
65. Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. *Cancer Res*. 2003; 63(19):6453–6457. [PubMed: 14559836]
66. Lowenstein H, Shah A, Chant A, Khan A. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. *Transpl Int*. 2006; 19(11):927–936. [PubMed: 17018129]
67. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. *Leukemia*. 2006; 20(2):272–279. [PubMed: 16341049]
68. Macedo C, Walters JT, Orkis EA, et al. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. *Transplantation*. 2012; 93(8):813–821. [PubMed: 22343334]
69. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. *Transplantation*. 2006; 82(10):1342–1351. [PubMed: 17130784]
70. Dons EM, Raimondi G, Zhang H, et al. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity. *Am J Transplant*. Aug; 2013 13(8):2169–2178. [PubMed: 23635093]
71. Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. *Immunology*. 2014; 141(1):123–131. [PubMed: 24116901]
72. De Serres SA, Mfarrej BG, Magee CN, et al. Immune profile of pediatric renal transplant recipients following alemtuzumab induction. *J Am Soc Nephrol*. 2012; 23(1):174–182. [PubMed: 22052056]
73. Bloom DD, Chang Z, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. *Am J Transplant*. 2008; 8(4):793–802. [PubMed: 18261176]
74. Toh BH, Kyaw T, Tipping P, Bobik A. Immune regulation by CD52-expressing CD4 T cells. *Cell Mol Immunol*. 2013; 10(5):379–382. [PubMed: 23934027]
75. Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. *Clin Immunol*. 2006; 120(3):247–259. [PubMed: 16797237]
76. Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. *J Immunol*. 2013; 191(12):5867–5874. [PubMed: 24198283]
77. Clark M, Cooke A. Regulation unmasked by activation. *Nat Immunol*. 2013; 14(7):696–697. [PubMed: 23778805]

78. Bandala-Sanchez E, Zhang Y, Reinwald S, et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. *Nat Immunol.* 2013; 14(7):741–748. [PubMed: 23685786]
79. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. *Nat Rev Immunol.* 2007; 7(4):255–266. [PubMed: 17380156]
80. Razi N, Varki A. Cryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activation. *Glycobiology.* 1999; 9(11):1225–1234. [PubMed: 10536038]
81. Kivi E, Elima K, Aalto K, et al. Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. *Blood.* 2009; 114(26):5385–5392. [PubMed: 19861682]
82. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: kidney. *Am J Transplant.* 2015; 15(Suppl 2):1–34.
83. Moes AD, Hesselink DA, Zietse R, van Schaik RH, van Gelder T, Hoorn EJ. Calcineurin inhibitors and hypertension: a role for pharmacogenetics? *Pharmacogenomics.* 2014; 15(9):1243–1251. [PubMed: 25141899]
84. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. *Transplantation.* 2004; 77(3):339–344. [PubMed: 14966405]
85. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. *Nat Rev Immunol.* 2015; 15(5):283–294. [PubMed: 25882245]
86. Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. *Immunol Rev.* 2011; 241(1):63–76. [PubMed: 21488890]
87. Miroux C, Morales O, Ghazal K, et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. *Transplantation.* 2012; 94(2):123–131. [PubMed: 22743548]
88. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. *Nat Immunol.* 2008; 9(2):194–202. [PubMed: 18157133]
89. Huehn J, Beyer M. Epigenetic and transcriptional control of Foxp3+ regulatory T cells. *Semin Immunol.* 2015; 27(1):10–18. [PubMed: 25801206]
90. Li X, Liang Y, LeBlanc M, Benner C, Zheng Y. Function of a Foxp3 cis-element in protecting regulatory T cell identity. *Cell.* 2014; 158(4):734–748. [PubMed: 25126782]
91. Akimova T, Kamath BM, Goebel JW, et al. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. *Am J Transplant.* 2012; 12(12):3449–3461. [PubMed: 22994804]
92. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. *Blood.* 2006; 108(1):390–399. [PubMed: 16522809]
93. Gallon L, Traitanon O, Yu Y, et al. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. *Transplantation.* Apr 22, 2015
94. Li Q, Shakya A, Guo X, et al. Constitutive nuclear localization of NFAT in Foxp3+ regulatory T cells independent of calcineurin activity. *J Immunol.* 2012; 188(9):4268–4277. [PubMed: 22490438]
95. Brandt C, Pavlovic V, Radbruch A, Worm M, Baumgrass R. Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. *Allergy.* 2009; 64(11):1588–1596. [PubMed: 19432936]
96. Calvo-Turrubiarres M, Romano-Moreno S, Garcia-Hernandez M, et al. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level. *Transpl Immunol.* 2009; 21(1):43–49. [PubMed: 19233271]
97. Vaeth M, Schliesser U, Muller G, et al. Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. *Proc Natl Acad Sci U S A.* Oct 2; 2012 109(40):16258–16263. [PubMed: 22991461]

98. Satake A, Schmidt AM, Archambault A, Lechner TM, Wu GF, Kambayashi T. Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory T cells while inhibiting conventional T cells. *J Autoimmun.* 2013; 44:13–20. [PubMed: 23834842]
99. Yamada Y, Nadazdin O, Boskovic S, et al. Repeated Injections of IL-2 Break Renal Allograft Tolerance Induced via Mixed Hematopoietic Chimerism in Monkeys. *Am J Transplant.* 2015; 15(12):3055–3066. [PubMed: 26190648]
100. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. *N Engl J Med.* 2011; 365(22):2055–2066. [PubMed: 22129252]
101. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. *Sci Transl Med.* Apr 3.2013 5(179):179ra143.
102. Kennedy-Nasser AA, Ku S, Castillo-Caro P, et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. *Clin Cancer Res.* 2014; 20(8):2215–2225. [PubMed: 24573552]
103. Siepert A, Ahrlich S, Vogt K, et al. Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells. *Am J Transplant.* 2012; 12(9): 2384–2394. [PubMed: 22702307]
104. Levitsky J, Mathew JM, Abecassis M, et al. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. *Hepatology.* 2013; 57(1):239–248. [PubMed: 22234876]
105. Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. *J Am Acad Dermatol.* 1997; 37(3 Pt 1): 445–449. [PubMed: 9308561]
106. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. *Transplantation.* 2005; 80(2 Suppl):S181–190. [PubMed: 16251851]
107. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. *J Biol Chem.* 1993; 268(36):7286–72790.
108. Mehling A, Grabbe S, Voskott M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. *J Immunol.* 2000; 165(5):2374–2381. [PubMed: 10946260]
109. Lim DG, Joe IY, Park YH, et al. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. *Transpl Immunol.* Nov; 2007 18(2):94–100. [PubMed: 18005851]
110. Abadja F, Atemkeng S, Alamartine E, Berthoux F, Mariat C. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. *Transplantation.* 2011; 92(4):396–403. [PubMed: 21818055]
111. Degauque N, Mariat C, Kenny J, et al. Immunostimulatory Tim-1-specific antibody deprograms Treg and prevents transplant tolerance in mice. *J Clin Invest.* 2008; 118(2):735–741. [PubMed: 18079964]
112. Abadja F, Videcoq C, Alamartine E, Berthoux F, Mariat C. Differential effect of cyclosporine and mycophenolic acid on the human regulatory T cells and TH-17 cells balance. *Transplantation proceedings.* 2009; 41(8):3367–3370. [PubMed: 19857751]
113. Lim DG, Koo SK, Park YH, et al. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation. *Transplantation.* 2010; 89(8):928–936. [PubMed: 20305583]
114. Demirkiran A, Sewgobind VD, van der Weijde J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. *Transplantation.* 2009; 87(7):1062–1068. [PubMed: 19352129]
115. Fourtounas C, Dousdampanis P, Sakellarakis P, et al. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients. *Am J Nephrol.* 2010; 32(1):1–9. [PubMed: 20484893]

116. Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. *Endocrinology*. 2013; 154(3):993–1007. [PubMed: 23384835]
117. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. *Endocr Rev*. 2003; 24(4):488–522. [PubMed: 12920152]
118. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. *Endocr Rev*. 1999; 20(4):435–459. [PubMed: 10453354]
119. Lowenberg M, Verhaar AP, van den Brink GR, Hommes DW. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. *Trends Mol Med*. 2007; 13(4):158–163. [PubMed: 17293163]
120. Muller N, Fischer HJ, Tischner D, van den Brandt J, Reichardt HM. Glucocorticoids induce effector T cell depolarization via ERM proteins, thereby impeding migration and APC conjugation. *J Immunol*. 2013; 190(8):4360–4370. [PubMed: 23475220]
121. Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. *Nat Med*. 2002; 8(5):473–479. [PubMed: 11984591]
122. Mahata B, Zhang X, Kolodziejczyk AA, et al. Single-cell RNA sequencing reveals T helper cells synthesizing steroids de novo to contribute to immune homeostasis. *Cell Rep*. 2014; 7(4):1130–1142. [PubMed: 24813893]
123. Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. *Crit Rev Clin Lab Sci*. 2005; 42(1):71–104. [PubMed: 15697171]
124. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. *Eur J Immunol*. 2006; 36(8):2139–2149. [PubMed: 16841298]
125. Suarez A, Lopez P, Gomez J, Gutierrez C. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. *Ann Rheum Dis*. 2006; 65(11):1512–1517. [PubMed: 16606650]
126. Karagiannidis C, Akdis M, Holopainen P, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. *J Allergy Clin Immunol*. Dec; 2004 114(6):1425–1433. [PubMed: 15577848]
127. Seissler N, Schmitt E, Hug F, et al. Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Treg-cells in transplanted patients. *Transpl Immunol*. 2012; 27(4):157–161. [PubMed: 23022208]
128. Bereshchenko O, Coppo M, Bruscoli S, et al. GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-beta signaling. *Cell Rep*. 2014; 7(2):464–475. [PubMed: 24703841]
129. Libert C, Dejager L. How steroids steer T cells. *Cell Rep*. 2014; 7(4):938–939. [PubMed: 24856295]
130. Garber K. Targeting mTOR: something old, something new. *J Natl Cancer Inst*. 2009; 101(5):288–290. [PubMed: 19244168]
131. Singh K, Sun S, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action. *J Antibiot (Tokyo)*. 1979; 32(6):630–645. [PubMed: 381274]
132. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol Cell*. 2006; 22(2):159–168. [PubMed: 16603397]
133. Loewith R, Jacinto E, Wullschlegel S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. *Mol Cell*. 2002; 10(3):457–468. [PubMed: 12408816]
134. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. *Nat Cell Biol*. 2004; 6(11):1122–1128. [PubMed: 15467718]

135. Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. *Nat Immunol.* 2011; 12(4):295–303. [PubMed: 21358638]
136. Pollizzi KN, Patel CH, Sun IH, et al. mTORC1 and mTORC2 selectively regulate CD8(+) T cell differentiation. *J Clin Invest.* 2015; 125(5):2090–2108. [PubMed: 25893604]
137. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. *Nature.* 2009; 460(7251):108–112. [PubMed: 19543266]
138. Spence A, Klementowicz JE, Bluestone JA, Tang Q. Targeting Treg signaling for the treatment of autoimmune diseases. *Curr Opin Immunol.* 2015; 37:11–20. [PubMed: 26432763]
139. Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. *Immunity.* 2009; 30(6):832–844. [PubMed: 19538929]
140. Huynh A, DuPage M, Priyadharshini B, et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. *Nat Immunol.* 2015; 16(2):188–196. [PubMed: 25559257]
141. Shrestha S, Yang K, Guy C, Vogel P, Neale G, Chi H. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. *Nature Immunol.* 2015; 16(2):178–187. [PubMed: 25559258]
142. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of p12 allows human T regulatory cells to preferentially expand in rapamycin. *J Immunol.* 2008; 180(9):5794–5798. [PubMed: 18424697]
143. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. *Blood.* 2008; 111(1):453–462. [PubMed: 17967941]
144. Battaglia M, Stabellini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. *Blood.* Jun 15; 2005 105(12):4743–4748. [PubMed: 15746082]
145. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. *Am J Transplant.* 2007; 7(7):1722–1732. [PubMed: 17511761]
146. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity. *Sci Transl Med.* 2011; 3(83):83ra41.
147. Ruggenenti P, Perico N, Gotti E, et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. *Transplantation.* 2007; 84(8):956–964. [PubMed: 17989600]
148. Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. *Am J Transplant.* 2015; 15(1):119–128. [PubMed: 25521535]
149. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. *Transplantation.* 2009; 87(2):233–242. [PubMed: 19155978]
150. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. *Nature.* Jul 25; 2013 499(7459):485–490. [PubMed: 23812589]
151. Vincenti F. Costimulation blockade in autoimmunity and transplantation. *J Allergy Clin Immunol.* 2008; 121(2):299–306. [PubMed: 18269922]
152. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. *Annu Rev Immunol.* 2001; 19:225–252. [PubMed: 11244036]
153. Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. *J Immunol.* 2003; 171(7):3348–3352. [PubMed: 14500627]
154. Meagher C, Tang Q, Fife BT, et al. Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. *J Immunol.* 2008; 180(12):7793–7803. [PubMed: 18523243]
155. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. *Euro J Immunol.* 2004; 34(11):2996–3005.

156. Liang S, Alard P, Zhao Y, Parnell S, Clark SL, Kosiewicz MM. Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. *J Exp Med*. 2005; 201(1):127–137. [PubMed: 15630140]
157. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. *Nat Immunol*. 2002; 3(11):1097–1101. [PubMed: 12368911]
158. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. *J Immunol*. 2009; 183(4):2475–2483. [PubMed: 19635913]
159. Yan Y, Zhang GX, Gran B, et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. *J Immunol*. 2010; 185(10):5953–5961. [PubMed: 20944000]
160. Deppong CM, Parulekar A, Boomer JS, Bricker TL, Green JM. CTLA4-Ig inhibits allergic airway inflammation by a novel CD28-independent, nitric oxide synthase-dependent mechanism. *Euro J Immunol*. 2010; 40(7):1985–1994.
161. Deppong CM, Bricker TL, Rannals BD, Van Rooijen N, Hsieh CS, Green JM. CTLA4Ig inhibits effector T cells through regulatory T cells and TGF-beta. *J Immunol*. 2013; 191(6):3082–3089. [PubMed: 23956428]
162. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). *Am J Transplant*. 2010; 10(3):535–546. [PubMed: 20415897]
163. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. *Am J Transplant*. 2013; 13(11):2875–2883. [PubMed: 24047110]
164. Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. *Am J Transplant*. 2014; 14(8):1817–1827. [PubMed: 25041339]
165. Clatworthy MR. Targeting B cells and antibody in transplantation. *Am J Transplant*. 2011; 11(7):1359–1367. [PubMed: 21668625]
166. Hamel KM, Cao Y, Ashaye S, et al. B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis. *J Immunol*. 2011; 187(9):4900–4906. [PubMed: 21948985]
167. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. *Arthritis Res Ther*. 2006; 8(3):R83. [PubMed: 16677395]
168. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. *Clin Immunol*. 2007; 122(1):62–74. [PubMed: 17046329]
169. Ray A, Basu S, Williams CB, Salzman NH, Dittel BN. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. *J Immunol*. 2012; 188(7):3188–3198. [PubMed: 22368274]
170. Kamburova EG, Koenen HJ, van den Hoogen MW, Baas MC, Joosten I, Hilbrands LB. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. *PLoS One*. 2014; 9(11):e112658. [PubMed: 25393622]
171. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. *Haematologica*. 2010; 95(11):1935–1942. [PubMed: 20663943]
172. Ratanatharathorn V, Logan B, Wang D, et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. *British journal of haematology*. 2009; 145(6):816–824. [PubMed: 19344418]
173. Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. *Leukemia*. 2006; 20(1):172–173. [PubMed: 16239908]
174. Aydogan M, Yologlu N, Gacar G, Uyan ZS, Eser I, Karaoz E. Successful rapid rituximab desensitization in an adolescent patient with nephrotic syndrome: Increase in number of Treg cells after desensitization. *J Allergy Clin Immunol*. 2013; 132(2):478–480. [PubMed: 23582516]

175. Sfrikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. *Clin Immunol.* 2007; 123(1):66–73. [PubMed: 17275413]
176. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. *Nat Rev Immunol.* 2010; 10(4):236–247. [PubMed: 20224569]
- i177. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. *J Am Acad Dermatol.* 2003; 49(2 Suppl):S87–97. [PubMed: 12894131]
178. Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. *J Clin Invest.* 2015; 125(8):3285–3296. [PubMed: 26193635]
179. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. *Nat Med.* 2009; 15(7):746–749. [PubMed: 19584865]
180. Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. *Am J Transplant.* 2011; 11(1):22–33. [PubMed: 21070604]
181. Lo DJ, Anderson DJ, Weaver TA, et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. *Am J Transplant.* 2013; 13(2):320–328. [PubMed: 23311611]
182. Lowe MC, Badell IR, Turner AP, et al. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. *Am J Transplant.* 2013; 13(2):312–319. [PubMed: 23279640]
183. Rostaing L, Charpentier B, Glyda M, et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. *Am J Transplant.* 2013; 13(7):1724–1733. [PubMed: 23730730]
184. Wojciechowski D, Vincenti F. Tofacitinib in kidney transplantation. *Expert Opin Investig Drugs.* 2013; 22(9):1193–1199.
185. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. *Science.* 2003; 302(5646):875–878. [PubMed: 14593182]
186. Buckley RH. The multiple causes of human SCID. *J Clin Invest.* 2004; 114(10):1409–1411. [PubMed: 15545990]
187. van Gurp EA, Schoordijk-Verschoor W, Klepper M, et al. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. *Transplantation.* 2009; 87(1):79–86. [PubMed: 19136895]
188. Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. *Am J Transplant.* 2012; 12(9):2446–2456. [PubMed: 22682022]
189. Sewgobind VD, Quaedackers ME, van der Laan LJ, et al. The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. *Am J Transplant.* 2010; 10(8):1785–1795. [PubMed: 20626385]
190. Fotino C, Pileggi A. Blockade of leukocyte function antigen-1 (LFA-1) in clinical islet transplantation. *Curr Diab Rep.* 2011; 11(5):337–344. [PubMed: 21755435]
191. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. *Am J Transplant.* 2007; 7(7):1770–1777. [PubMed: 17564637]
192. Posselt AM, Bellin MD, Tavakol M, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. *Am J Transplant.* 2010; 10(8):1870–1880. [PubMed: 20659093]
193. Hurst SM, Wilkinson TS, McLoughlin RM, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. *Immunity.* 2001; 14(6):705–714. [PubMed: 11420041]

194. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity*. 2006; 24(2):179–189. [PubMed: 16473830]
195. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. *Science*. 2003; 299(5609):1033–1036. [PubMed: 12532024]
196. Lal G, Yin N, Xu J, et al. Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of Foxp3 expression and Treg function. *Am J Transplant*. 2011; 11(2):203–214. [PubMed: 21219575]
197. Samanta A, Li B, Song X, et al. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. *Proc Natl Acad Sci U S A*. 2008; 105(37):14023–14027. [PubMed: 18779564]
198. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. *Ann Rev Med*. 2000; 51:245–270. [PubMed: 10774463]
199. Exterkate L, Slegtenhorst BR, Kelm M, et al. Frailty and Transplantation. *Transplantation*. 2016; 100(4):727–733. [PubMed: 26703348]
200. Samson M, Audia S, Janikashvili N, et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. *Arthritis Rheum*. 2012; 64(8):2499–2503. [PubMed: 22488116]
201. Pesce B, Soto L, Sabugo F, et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. *Clin Exp Immunol*. 2013; 171(3):237–242. [PubMed: 23379428]
202. Lei J, He F, Wu M, Zheng X, Chen X, Chen Z. Administration of anti-interleukin-6 monoclonal antibody prolongs cardiac allograft survival. *Transpl Int*. 2010; 23(12):1271–1281. [PubMed: 20646257]
203. Wang H, Guan Q, Lan Z, et al. Prolonged renal allograft survival by donor interleukin-6 deficiency: association with decreased alloantibodies and increased intra-graft T regulatory cells. *Am J Physiol Renal Physiol*. 2012; 302(2):F276–283. [PubMed: 22031852]
204. Fogal B, Yi T, Wang C, et al. Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells. *J Immunol*. Dec 15; 2011 187(12): 6268–6280. [PubMed: 22084439]
205. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. *Am J Transplant*. 2008; 8(9):1911–1920. [PubMed: 18786233]
206. Casiraghi F, Ruggenenti P, Noris M, et al. Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. *Transplantation*. May 27; 1997 63(10):1508–1514. [PubMed: 9175818]
207. Liang Y, Christopher K, Finn PW, Colson YL, Perkins DL. Graft produced interleukin-6 functions as a danger signal and promotes rejection after transplantation. *Transplantation*. 2007; 84(6):771–777. [PubMed: 17893611]
208. Waiser J, Budde K, Katalinic A, Kuerzdorfer M, Riess R, Neumayer HH. Interleukin-6 expression after renal transplantation. *Nephrol Dial Transplant*. 1997; 12(4):753–759. [PubMed: 9141007]
209. Martin J, Worthington J, Harris S, Martin S. The influence of class II transactivator and interleukin-6 polymorphisms on the production of antibodies to donor human leucocyte antigen mismatches in renal allograft recipients. *Int J Immunogenet*. 2009; 36(4):235–239. [PubMed: 19523152]
210. Kocierz M, Siekiera U, Kolonko A, et al. -174G/C interleukin-6 gene polymorphism and the risk of transplanted kidney failure or graft loss during a 5-year follow-up period. *Tissue Antigens*. 2011; 77(4):283–290. [PubMed: 21388350]
211. Kim I, Wu G, Chai NN, Klein AS, Jordan S. Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. *Transplantation*. 2014; 98(12): 1262–1270. [PubMed: 25286051]

212. Vo AA, Choi J, Kim I, et al. A Phase I/II Trial of the Interleukin-6 Receptor Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. Transplantation. 2015
213. Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol. 2014; 10(1):14–24. [PubMed: 24100403]
214. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007; 27(1):111–122. [PubMed: 17629517]
215. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews. Cancer. 2012; 12(4):252–264. [PubMed: 22437870]
216. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014; 32(19):e69–71. [PubMed: 24493726]
217. Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother. 2015; 38(5):211. [PubMed: 25962109]
218. Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Can. 2015; 3:22.
219. Lipson EJ, Bagnasco SM, Moore J Jr. et al. Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. N Engl J med. 2016; 374(9):896–898.
220. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016; 27(6):1135–7. [PubMed: 26951628]
221. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl j Med. 2006; 355(10):1018–1028. [PubMed: 16908486]
222. Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood. 2003; 102(2):564–570. [PubMed: 12649149]
223. Zhang T, Fresnay S, Welty E, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant. 2011; 11(8):1599–1609. [PubMed: 21749640]
224. Poirier N, Blancho G, Vanhove B. CD28-specific immunomodulating antibodies: what can be learned from experimental models? Am J Transplant. 2012; 12(7):1682–1690. [PubMed: 22471377]
225. Poirier N, Dilek N, Mary C, et al. FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. Am J Transplant. 2015; 15(1):88–100. [PubMed: 25488654]
226. Mary C, Coulon F, Poirier N, et al. Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain. mAbs. 2013; 5(1):47–55. [PubMed: 23221503]
227. Poirier N, Azimzadeh AM, Zhang T, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med. 2010; 2(17):17ra10.
228. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006; 108(1):253–261. [PubMed: 16537805]
229. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004; 200(3):277–285. [PubMed: 15280421]
230. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007; 204(1):33–39. [PubMed: 17200409]

231. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. *Am J Transplant*. 2012; 12(6): 1576–1583. [PubMed: 22494609]
232. Amrani A, Serra P, Yamanouchi J, et al. CD154-dependent priming of diabetogenic CD4(+) T cells dissociated from activation of antigen-presenting cells. *Immunity*. 2002; 16(5):719–732. [PubMed: 12049723]
233. Serra P, Amrani A, Yamanouchi J, et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. *Immunity*. 2003; 19(6):877–889. [PubMed: 14670304]
234. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. *Nat Med*. Feb.2000 6(2):114.
235. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. *Nat Med*. Mar; 2002 8(3):247–252. [PubMed: 11875495]
236. Shock A, Burkly L, Wakefield I, et al. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. *Arthritis research & therapy*. 2015; 17:234. [PubMed: 26335795]
237. Tocioian A, Buchan P, Kirby H, et al. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. *Lupus*. 2015; 24(10):1045–1056. [PubMed: 25784719]
238. Goldwater R, Keirns J, Blahunka P, et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. *Am J Transplant*. 2013; 13(4): 1040–1046. [PubMed: 23356210]
239. Ma A, Dun H, Song L, et al. Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys. *Transplantation*. 2014; 97(4):397–404. [PubMed: 24389907]
240. Dai H, Peng F, Lin M, et al. Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40/CD40L and LFA-1/ICAM-1 blockade. *Transpl Immunol*. 2015; 32(2): 84–91. [PubMed: 25613092]
241. Wang H, Zhang Z, Tian W, et al. Memory T Cells Mediate Cardiac Allograft Vasculopathy and are Inactivated by Anti-OX40L Monoclonal Antibody. *Cardiovasc Drugs Ther*. 2014; 28(2):115–122. [PubMed: 24254032]
242. Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. *J Immunol*. Jan 15; 2012 188(2):892–901. [PubMed: 22147766]
243. Vu MD, Xiao X, Gao W, et al. OX40 costimulation turns off Foxp3+ Treg. *Blood*. Oct 1; 2007 110(7):2501–2510. [PubMed: 17575071]
244. Demirci G, Li XC. Novel roles of OX40 in the allograft response. *Curr Opin Organ Transplant*. 2008; 13(1):26–30. [PubMed: 18660703]
245. Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: a helpful immunomodulator. *Immunology*. 2011; 134(2):123–139. [PubMed: 21896008]
246. Obi Y, Hamano T, Ichimaru N, et al. Vitamin D deficiency predicts decline in kidney allograft function: a prospective cohort study. *The Journal of clinical endocrinology and metabolism*. 2014; 99(2):527–535. [PubMed: 24285688]
247. Kim H, Kang SW, Yoo TH, et al. The impact of pretransplant 25-hydroxy vitamin D deficiency on subsequent graft function: an observational study. *BMC nephrology*. 2012; 13:22. [PubMed: 22533967]
248. Lowery EM, Bemiss B, Cascino T, et al. Low vitamin D levels are associated with increased rejection and infections after lung transplantation. *J Heart Lung Transplant*. 2012; 31(7):700–707. [PubMed: 22386448]
249. Hamid K, Yusoff A, Rahman M, Mohamad M, Hamid A. Effective connectivity between superior temporal gyrus and Heschl's gyrus during white noise listening: linear versus non-linear models. *Biomed Imaging Interv J*. 2012; 8(2):e13. [PubMed: 22970069]

Figure 1. Mechanisms of action of immunosuppressive drugs on T cell activation

Schematic representation of the mechanisms of action by which immunosuppressants control T cell activation. Black font marks molecules expressed by T cells and antigen presenting cells (APC). Red font marks immunosuppressive drugs. Black arrows indicate signaling pathways and red T-bars point to targets of immunosuppressive drugs.

Figure 2. Differential effects of immunosuppressive drugs on the balance between effector T cells and Treg

Immunosuppressive drugs are represented by colored blocks. The overall length of the block roughly correlates with the drug's immunosuppressive potency. The left-right position of the block indicates the drug's selectivity for effector T cells (Teff) versus Treg with the center position representing no selectivity and left to the center more suppressive for Teff than for Treg. The overall height of the balance in the cylinder below correlates with state of immune activity and the tilt of the balance correlates with regulatory activity.